Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are inflammatory disorders of the vasculature.

  • PMR affects the limbs, causing pain, stiffness and motion limitation. PMR prevalence is 0.5-0.7% among adults 50 or older.

  • GCA affects head vessels, causing severe headaches and jaw pain. GCA can lead to blindness, stroke or aneurysm. GCA prevalence is about 0.2% among adults 50 or older.

  • The diseases occur together: about 15% of PMR patients have GCA, and about 50% of GCA patients have PMR.

  • Both diseases occur more frequently in women.  

 

Here's why a safer oral corticosteroid is needed for PMR and GCA.

  • Together, they are the #1 reason for long-term oral corticosteroid prescription. Patients are generally prescribed oral corticosteroids for a year or longer.

  • CS are the only FDA-approved drugs for PMR. Tocilizumab is indicated to treat GCA in combination with CS. Methotrexate is used off-label, most often together with a corticosteroid.

  • There is a very limited pipeline of biologics to treat GCA currently in Phase 2 or Phase 3 clinical trials.

  • Typical patients are older women, who are at increased risk for fractures and other corticosteroid side effects.

 

Additional promising indications for a safer oral corticosteroid include asthma/chronic obstructive pulmonary disease (#1 reason for oral corticosteroid prescription), rheumatoid arthritis, and lymphomas and leukemias. Patients with an elevated corticosteroid side effect risk include the elderly and those with diabetes.

copyright (c) 2019 Sparrow Pharmaceuticals, Inc.